Frontlight ResearchEarly access
TerminatedNo phase
Digital Remote Home Monitoring for Heart Failure
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- People taking part
- 15 people enrolled
- Started
- 13 Dec 2024
- Ended
- 30 Nov 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Biofourmis Digital Platform
- Record updated
- 18 February 2026
- Why it stopped
- Due to sponsor request for poor enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- ≥18-year-old adults with a clinical diagnosis of heart failure AND a left ventricular ejection fraction ≤40% by transthoracic echocardiogram or cardiac MRI within 12 months prior to enrollment
Who cannot take part
- Recent or home inotropic therapy, or heart transplant evaluation
- End-stage renal disease, receiving dialysis or eGFR ≤30 mL/min/1.73m2
- Patients who are pregnant
- Patients who do not have a smartphone or access to the Internet
- Prisoners or refugees
- Patients who are homeless or have unstable housing
- Unable or unwilling to consent or use study related materials
- On-going cocaine, methamphetamine, opioid, alcohol, or other illicit substance abuse as determined by the study PI
- Not fluent in English or Spanish
- Students or trainees at UT-Southwestern or Parkland Health System
- Enrolled or considering hospice
- Survival anticipated <6 months
- Non-Texas resident
Where in United States
- Parkland Health & Hospital SystemDallas, United States
- UT Southwestern Medical CenterDallas, United States
About the trial
What the trial wants to find out
We will enroll 150 adult participants with systolic heart failure into the ADHERE-HF trial. The study will randomize participants in a 1:2 fashion to usual care or usual care plus the American Heart Association's Digital Solution for 90 days. This wearable device and careplan package is hypothesized to improve rates of guideline directed heart failure medical care for participants.
The 2 groups in the trial
- DeviceTreatment being tested
Participants will receive usual care or usual care plus the American Heart Association's Digital Solution in patients with HFrEF. The Solution is a combination of the AHA/CHTI HF CarePlans and Education Content, delivered through and combined with the Biofourmis Platform.
Treatment: Biofourmis Digital Platform
- Routine CareNo study treatment, for comparison
Routine care for heart failure management
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- American Heart Association Digital Home Remote Monitoring for Heart Failure
- Record updated
- 18 February 2026